Aparna Kailasam, MD, MBA, MS
she/her/hers
Assistant Professor of Obstetrics, Gynecology & Reproductive SciencesDownloadHi-Res Photo
Cards
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Copy Link
Titles
Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences
Appointments
Obstetrics, Gynecology & Reproductive Sciences
Assistant ProfessorPrimary
Other Departments & Organizations
- Gynecologic Oncology Program
- Obstetrics, Gynecology & Reproductive Sciences
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Fellowship
- Mayo Clinic (2024)
- MS
- Mayo Clinic Graduate School of Biomedical Sciences, Clinical and Translational Science (2024)
- Residency
- St. Francis Hospital & Medical Center (2021)
- MD
- Creighton University School of Medicine, Medicine (2017)
- MBA
- University of Denver, International Business (2013)
- BS
- University of Denver, Molecular Biology (2013)
Research
Copy Link
Overview
Public Health Interests
Cancer; Community Health; Genetics, Genomics, Epigenetics; Global Health; Health Care Quality, Efficiency
ORCID
0000-0003-3250-8629
Research at a Glance
Yale Co-Authors
Frequent collaborators of Aparna Kailasam's published research.
Publications Timeline
A big-picture view of Aparna Kailasam's research output by year.
Alessandro Santin, MD
Blair McNamara, MD
Elena Ratner, MD, MBA
Victoria M. Ettorre, DO, MS
Katyayani (Katya) Papatla, MD, MPH
Mitchell Clark, MD, MPH
16Publications
283Citations
Publications
2026
A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Ottum S, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932). Journal Of Clinical Oncology 2026, 44: 5575-5575. DOI: 10.1200/jco.2026.44.16_suppl.5575.Peer-Reviewed Original ResearchConceptsPlatinum-resistant ovarian cancerSacituzumab govitecanPhase II evaluationOvarian cancerOpen-label phase II studyActive metaboliteTreatment-emergent adverse eventsHigh-grade serous ovarian cancerMarkers of aggressive diseaseActive metabolite of irinotecanIntravenously day 1Phase II studyMedian Follow-UpECOG performance statusMetabolite of irinotecanFrequent grade 1Serous ovarian cancerAntibody-drug conjugatesMedian PFSMedian OSProgression-FreeSerous histologyStable diseaseAbdominal painStage III/IVA Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. Clinical Cancer Research 2026, of1-of10. PMID: 42132892, DOI: 10.1158/1078-0432.ccr-26-0144.Peer-Reviewed Original ResearchAltmetricConceptsProgression-free survivalDuration of responseOverall survivalSacituzumab govitecanH-scoreEndometrial cancerGrade 3 endometrioid tumorsMedian duration of responseMedian progression-free survivalClinical benefit rateRecurrent uterine cancerMedian Follow-UpTrop-2 expressionPhase II evaluationMean H scoreAdvanced/recurrent ECRecurrent ECSerous carcinomaPretreated populationTrop-2Primary endpointSecondary endpointsUterine cancerBenefit rateSafety profileSurvival benefit of interventions for malignant biliary obstruction in gynecologic oncology patients
Greenman M, Ferrucci C, Abozenah Y, Ettorre V, Ottum S, McNamara B, Papatla K, Kailasam A, Dottino P, Clark M, Ratner E, Santin A, Azodi M, Altwerger G. Survival benefit of interventions for malignant biliary obstruction in gynecologic oncology patients. Gynecologic Oncology 2026, 208: s288-s289. DOI: 10.1016/j.ygyno.2026.01.510.Peer-Reviewed Original ResearchReal World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status
Dzienny A, Abozenah Y, Griffith J, Sohail S, Pan Y, Vlamis C, Yamartino K, Leclair J, Israel G, Greenman M, McNamara B, Azodi M, Ratner E, Santin A, Dottino P, Papatla K, Kailasam A, Hui P, Buza N, Altwerger G. Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status. Gynecologic Oncology Reports 2026, 65: 102084. PMID: 42095053, PMCID: PMC13139971, DOI: 10.1016/j.gore.2026.102084.Peer-Reviewed Original ResearchAltmetricConceptsProgression-free survivalRecurrent endometrial cancerOptimal starting doseDose of lenvatinibHigh-grade tumorsP53 mutationsEndometrial cancerLenvatinib dosePlatinum resistanceP53 statusStarting doseAssociated with prolonged progression-free survivalPlatinum statusProlonged progression-free survivalOutcomes of pembrolizumabStandard starting doseEfficacy of pembrolizumabHigh-grade histologyIndividualized dosing strategiesMedian treatment durationBiomarkers of responseReal-world outcomesFewer dose reductionsReal-world cohortLow dose groupThe progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer
Kailasam A, De Vitis L, Murphy B, Cucinella G, Hopkins M, Fought A, Glaser G, Mariani A, Cliby W, Langstraat C. The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer. Gynecologic Oncology 2026, 208: 48-53. PMID: 41886941, DOI: 10.1016/j.ygyno.2026.03.004.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEarly stage endometrioid endometrial cancerManagement of endometrial cancerAbnormal p53 expressionMismatch repair deficiencyRetrospective cohort studyAtypical hyperplasiaEndometrial cancerNonsurgical managementP53 expressionResponse rate to hormonal therapyMolecular testingRetrospective cohort study of patientsCohort study of patientsP53-mutated tumorsPartial pathological responseConservative managementEndometrioid endometrial cancerFactors associated with responseStudy of patientsFisher's exact testAssociation of responseOral progesteroneProgestin therapyMyometrial invasionMolecular prognosticators
2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significance
2024
Understanding the patient experience in nonsurgical management of endometrial cancer and complex atypical hyperplasia due to obesity: A qualitative analysis
Kailasam A, Jatoi A, Reynolds E, Cliby W, Langstraat C. Understanding the patient experience in nonsurgical management of endometrial cancer and complex atypical hyperplasia due to obesity: A qualitative analysis. Gynecologic Oncology Reports 2024, 54: 101425. PMID: 38854684, PMCID: PMC11157205, DOI: 10.1016/j.gore.2024.101425.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEarly-stage endometrial cancerComplex atypical hyperplasiaPatient experienceEmotional impact of diagnosisSemi-structured phone interviewsAtypical hyperplasiaEndometrial cancerPerception of obesityManagement of endometrial cancerEffective therapeutic relationshipImpact of diagnosisClass 3 obesityGrade 1 ECSignificant medical comorbiditiesStandard surgical managementNon-surgical managementLong-term outcomesPhone interviewsAudio-recordedUterine preservationProgestin therapyEmotional impactTherapeutic relationshipSurgical managementDiagnostic workup
2023
Nonsurgical management of early-stage endometrial cancer due to obesity: a survey of the practice patterns of current Society of Gynecologic Oncology members
Kailasam A, Cucinella G, Fought A, Cliby W, Mariani A, Glaser G, Langstraat C. Nonsurgical management of early-stage endometrial cancer due to obesity: a survey of the practice patterns of current Society of Gynecologic Oncology members. Gynecologic Oncology Reports 2023, 50: 101280. PMID: 37927533, PMCID: PMC10623145, DOI: 10.1016/j.gore.2023.101280.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSociety of Gynecologic OncologyClass 3 obesityManagement of endometrial cancerPractice typePractice patternsEndometrial cancerNonsurgical managementGynecologic oncologistsBMI cutoffsManagement of early-stage endometrial cancerClass 3 obese patientsEarly-stage endometrial cancerGeographic regionsPhysicians' opinionsProgesterone intrauterine deviceComplex atypical hyperplasiaComplex patientsFisher's exact testEvaluate trendsLack of consensusOnline surveyObesityAtypical hyperplasiaIntrauterine deviceNonsurgical approach
2022
Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review
Kailasam A, Langstraat C. Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review. Current Treatment Options In Oncology 2022, 23: 1818-1828. PMID: 36417148, DOI: 10.1007/s11864-022-01031-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsHormone receptor-positiveRecurrent endometrial cancerLow-grade diseaseHormone therapyEndometrial cancerReceptor-positiveSurgical candidatesTreatment optionsGonadotropin-releasing hormone agonistHormone treatmentLevonorgestrel intrauterine deviceSecond-line treatmentHormonal treatment optionsEstrogen receptor modulatorsAnti-estrogen treatmentEndometrial cancer treatmentLow performance statusStandard of careOral progesteroneUpfront settingMetastatic diseaseIntrauterine deviceProgesterone receptorPerformance statusHormone agonist
2021
Impact of the availability of midurethral slings on treatment strategies for stress urinary incontinence: a cost‐effectiveness analysis
Chang O, Cadish L, Kailasam A, Ridgeway B, Shepherd J. Impact of the availability of midurethral slings on treatment strategies for stress urinary incontinence: a cost‐effectiveness analysis. BJOG An International Journal Of Obstetrics & Gynaecology 2021, 129: 500-508. PMID: 34314554, DOI: 10.1111/1471-0528.16850.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsStress urinary incontinenceMidurethral slingIncremental cost-effectiveness ratioUrinary incontinenceSurgical optionsTreatment strategiesIncontinence pessaryNo treatmentManagement of stress urinary incontinencePhysical therapyPelvic floor physical therapyMultiple one-way sensitivity analysesCost-effectiveness analysisDe novo urgencyUrethral bulking injectionsLaparoscopic Burch colposuspensionOne-way sensitivity analysesNon-surgical managementSurgical treatment optionsCost-effective surgical optionCost-effectiveness ratioAutologous slingSUI treatmentBurch colposuspensionSurgical retreatment
Academic Achievements & Community Involvement
Copy Link
Activities
activity Society of Gynecologic Oncology Legislative & Regulatory Affairs Subcommittee
03/14/2022 - PresentProfessional OrganizationsMember
Honors
honor Fellow Excellence in Teaching Award
05/06/2024Hospital System AwardMayo Clinic, Department of Obstetrics & GynecologyDetailsUnited Stateshonor Trainee Spotlight Award for Outstanding Published Article
12/01/2023National AwardGynecologic Oncology Reportshonor Outstanding MIS Resident Award
06/17/2021Hospital System AwardSociety of Laparoscopic & Robotic Surgeonshonor Salvatore Carrabba Research Award for Outstanding Resident Research Project
06/17/2021Hospital System AwardSt. Francis Hospital & Medical Center, Department of Obstetrics & Gynecologyhonor Recognition of Excellence in Minimally Invasive Gynecology
06/08/2020Hospital System AwardAAGL Award for PGY3
Clinical Care
Copy Link
Overview
Aparna Kailasam, MD, is a gynecologic oncologist specializing in the comprehensive care of gynecologic cancers, including both surgical and medical management.
Dr. Kailasam is dedicated to forming relationships with her patients, offering reassurance and support throughout their treatment journey. “The long-term relationships that I get to build with my patients and seeing when things go well is extremely rewarding,” she says. "’We are your team now and we will be your team through this whole process,’ I tell patients.”
As an assistant professor at Yale School of Medicine, Dr. Kailasam's research interests include cancer, community health, genetics, genomics, epigenetics, global health, and healthcare quality. Her work aims to improve patient care and outcomes in these areas. She is passionate about women's health advocacy and furthering education within her field.
Dr. Kailasam received her medical degree from Creighton University School of Medicine and completed her fellowship in gynecologic oncology at the Mayo Clinic. She completed her residency at St. Francis Hospital & Medical Center in Hartford.
Clinical Specialties
Gynecologic Oncology
Board Certifications
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 2024
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
Get In Touch
Copy Link
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.